NCT02987400 is a Phase 2 clinical trial of Venetoclax in Lymphoma, Large B-Cell, Diffuse, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie.

Who is sponsoring NCT02987400?

NCT02987400 is sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie.

What drugs are being tested in NCT02987400?

Interventions in NCT02987400: Venetoclax, Obinutuzumab.

What condition does NCT02987400 study?

NCT02987400 studies Lymphoma, Large B-Cell, Diffuse.

Is NCT02987400 still recruiting?

NCT02987400 is currently completed. Last updated 16 February 2022.

Last reviewed 2022-02-16 · How we verify

NCT02987400

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Completed Phase 2 Last updated 16 February 2022

What this trial tests

Phase 2 trial testing Venetoclax in Lymphoma, Large B-Cell, Diffuse in 22 participants. Completed in 19 October 2021.

Timeline

4 January 2017

Primary endpoint
19 October 2021

19 October 2021

Quick facts

Lead sponsor	Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	4 January 2017
Primary completion	19 October 2021
Estimated completion	19 October 2021
Sites	6 locations across Austria

Drugs / interventions tested

Venetoclax (venetoclax) — full drug profile →
Obinutuzumab — full drug profile →

Conditions studied

Lymphoma, Large B-Cell, Diffuse — all drugs for Lymphoma, Large B-Cell, Diffuse →

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie — full company profile →

Who can join

18 and older, any sex, with Lymphoma, Large B-Cell, Diffuse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the clinical activity and tolerability of a combination of obinutuzumab plus venetoclax in patients with relapsed or refractory diffuse large B-cell lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Pathways and mechanisms of venetoclax resistance.
Bose P, Gandhi V, Konopleva M. · · 2017 · cited 223× · PMID 28140720 · DOI 10.1080/10428194.2017.1283032
BCL-2 as therapeutic target for hematological malignancies.
Perini GF, Ribeiro GN, Pinto Neto JV, Campos LT, et al · · 2018 · cited 153× · PMID 29747654 · DOI 10.1186/s13045-018-0608-2
New agents and regimens for diffuse large B cell lymphoma.
Wang L, Li LR, Young KH. · · 2020 · cited 109× · PMID 33317571 · DOI 10.1186/s13045-020-01011-z
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.
Follini E, Marchesini M, Roti G. · · 2019 · cited 52× · PMID 31226848 · DOI 10.3390/ijms20123021
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies.
Yue X, Chen Q, He J. · · 2020 · cited 51× · PMID 33292251 · DOI 10.1186/s12935-020-01614-z
Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.
Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, et al · · 2019 · cited 39× · PMID 30881917 · DOI 10.3389/fonc.2019.00107
Development of venetoclax for therapy of lymphoid malignancies.
Zhu H, Almasan A. · · 2017 · cited 21× · PMID 28331288 · DOI 10.2147/dddt.s109325
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.
Lu T, Zhang J, Xu-Monette ZY, Young KH. · · 2023 · cited 19× · PMID 37580826 · DOI 10.1186/s40164-023-00432-z

Verify or expand the search:

Other trials of Venetoclax

Trials testing the same drug.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting

Other recruiting trials for Lymphoma, Large B-Cell, Diffuse

Currently open trials in the same condition.

NCT06890884 — A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R- · Phase 2 · recruiting
NCT06254495 — A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers · Phase 1 · active not recruiting
NCT06093841 — Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL · Phase 2 · active not recruiting
NCT05800366 — A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma · Phase 2 · recruiting
NCT05798156 — Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell · Phase 2 · active not recruiting

Other Arbeitsgemeinschaft medikamentoese Tumortherapie trials

Trials by the same sponsor.

NCT06294652 — AGMT Austrian Lymphoma Registry · recruiting
NCT06250465 — AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry · recruiting
NCT03984214 — Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Panc · Phase 3 · completed
NCT03792763 — Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients · Phase 2 · completed
NCT03301493 — Genomic Testing and Resulting Medical Decisions · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02987400 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arbeitsgemeinschaft medikamentoese Tumortherapie
Last refreshed: 16 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02987400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing